

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10597619	
Filing Date	2006-08-01	
First Named Inventor	BERGMANN et al.	
Art Unit		
Examiner Name		
Attorney Docket Number	2582.013	

**U.S.PATENTS**

**[Remove]**

Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

**[Add]**

**U.S.PATENT APPLICATION PUBLICATIONS**

**[Remove]**

Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

**[Add]**

**FOREIGN PATENT DOCUMENTS**

**[Remove]**

Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T <sup>5</sup>
	1	0217542	EP	i	1987-08-04	Ube Industries, Ltd.		<input type="checkbox"/>
	2	94/22016	WO		1994-09-29	REPINE et al.		<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

**[Add]**

**NON-PATENT LITERATURE DOCUMENTS**

**[Remove]**

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10597619	
Filing Date	2006-08-01	
First Named Inventor	BERGMANN et al.	
Art Unit		
Examiner Name		
Attorney Docket Number	2582.013	

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T5
	1	BECK Y. et al., "Human Mn superoxide dismutase cDNA sequence"; Nucleic Acids Research Vol 15(21) (1987), 9076.	<input type="checkbox"/>
	2	HJALMARSSON K. et al., "Isolation and sequence of complementary DNA encoding human extracellular superoxide dismutase"; Proc. Natl. Acad. Sci. U.S.A. 84:6340-6344 (1987).	<input type="checkbox"/>
	3	JOSEPH BZ et al., "Activities of Superoxide Dismutases and NADPH oxidase in neutrophils obtained from asthmatic and normal donors"; Inflammation 1993; 17(3):361-370.	<input type="checkbox"/>
	4	MISRA HP et al., "The role of superoxide anion in the autoxidation of epinephrine and a simple assay for superoxide dismutase"; J. Biol. Chem. 1971; 247(10): 3170-3175.	<input type="checkbox"/>
	5	Product Information and Manual: human Cu/Zn SOD ELISA BMS222, Bender MedSystems, MedSystems Diagnostics GmbH, Rennweg 95b, A-1030 Vienna, Austria (3.9.1997).	<input type="checkbox"/>
	6	TAYSI et al., "Serum oxidant/antioxidant status of patients with systemic lupus erythematosus", Clin Chem Lab Med 2002, 40(7): 684-688.	<input type="checkbox"/>
	7	Niels C. RIEDEMANN et al., "The Enigma of Sepsis", J. Clin. Invest. 112: 460-467 (2003).	<input type="checkbox"/>
	8	WARREN HS et al., "Risks and benefits of activated protein C treatment for severe sepsis", N Engl J Med 2002, 347 (13): 1027-1030.	<input type="checkbox"/>
	9	SIEGEL JP, "Assessing the use of activated protein C in the treatment of severe sepsis", N Engl J Med 2002; 347(13): 1030-1034.	<input type="checkbox"/>
	10	MANNS BJ et al., "An Economic Evaluation of Activated Protein C Treatment for Severe Sepsis", N Engl J Med., Vol. 347(13), 2002, 993-1000.	<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10597619
Filing Date	2006-08-01
First Named Inventor	BERGMANN et al.
Art Unit	
Examiner Name	
Attorney Docket Number	2582.013

	11	GOTZ et al., "Gastric mucosal superoxide dismutases in Helicobacter pylori infection", GUT, 38(4): 502-506, 1996.	<input type="checkbox"/>
	12	KRUIDENIER et al., "Differential mucosal expression of three superoxide dismutase isoforms in inflammatory bowel disease", JOURNAL OF PATHOLOGY, 201(1) September 2003, 7-16.	<input type="checkbox"/>
	13	FUNASAKA KUNIHIKO, "Change of superoxide dismutase content and its immunohistochemical localization in human thyroid tumors", MEDICAL JOURNAL OF KINKI UNIVERSITY, 20(2), 309-323, 1995. Abstract and figure legends.	<input type="checkbox"/>
	14	HASS et al., "The Effect of Bacterial Endotoxin on Synthesis of (Cu,Zn) Superoxide Dismutase in Lungs of Oxygen-exposed Rats", in: Journal of Biological Chemistry. Vol. 257(16), 9379-9383, 1982.	<input type="checkbox"/>
	15	ASAYAMA et al., "Selective Induction of Manganese Superoxide Dismutase in Human Monocytes", in: Am.J. Physiol. 249, C393-C397, 1985.	<input type="checkbox"/>
	16	IQBAL et al., "Endotoxin Increases Lung Cu,Zn Superoxide Dismutase mRNA: O <sub>2</sub> raises enzyme synthesis", in: Am.J. Physiol 257, L61-L64, 1989.	<input type="checkbox"/>
	17	VISNER et al., "Regulation of Manganese Superoxide Dismutase by Lipopolysaccharide, Interleukin-1, and Tumor Necrosis Factor", in: J. Biol. Chem. Vol. 265(5), Issue Feb. 15, 2856-2864, 1990.	<input type="checkbox"/>
	18	GORECKI et al., "Recombinant Human Superoxide Dismutases: Production and Potential Therapeutic Uses", in: Free Rad. Res. Comms., Vols. 12-13, 401-410, 1991.	<input type="checkbox"/>
	19	KONG et al., "Regulation of Cu, Zn-Superoxide Dismutase in Bovine Pulmonary Artery Endothelial Cells", in: Journal of Cellular Physiology, 153:491-497 (1992).	<input type="checkbox"/>
	20	GIBBS et al., "Mn and Cu/Zn SOD Expression in Cells from LPS-sensitive and LPS-resistant Mice", in: Free Radical Biology & Medicine, Vol. 12, 107-111, 1992.	<input type="checkbox"/>
	21	LEEFF et al., "Serum Antioxidants as predictors of adult respiratory distress syndrome in patients with Sepsis", in: Lancet 1993, 341: 777-780.	<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10597619
Filing Date	2006-08-01
First Named Inventor	BERGMANN et al.
Art Unit	
Examiner Name	
Attorney Docket Number	2582.013

22	MOKUNO et al., "Induction of Manganese Superoxide Dismutase by Cytokines and Lipopolysaccharides in Cultured Mouse Astrocytes", in J.Neurochem. 63, 612-616 (1994).	<input type="checkbox"/>
23	ABE et al., "Lipopolysaccharide Induces Manganese Superoxide Dismutase in the Rat Pancreas: Its Role in Caerulien Pancreatitis", in: Biochem.Biophys.Res.Comm., Vol. 217,(3), 1216-1222, 1995.	<input type="checkbox"/>
24	WARNER et al., "Prognostic Role of Antioxidant Enzymes in Sepsis: Preliminary Assessment", in: Clin.Chem. 41/6, 867-871 (1995).	<input type="checkbox"/>
25	GHOSH et al., "Tissue Differences in Antioxidant Enzyme Gene Expression in Response to Endotoxin", in: Free Rad. Biol. Med., Vol. 21(4), 533-540, 1996.	<input type="checkbox"/>
26	LEACH et al., "Decline in the expression of copper/zinc superoxide dismutase in the kidney of rats with endotoxic shock: Effects of the superoxide anion radical scavenger, tempol, on organ injury", in: Br. J. Pharmacol., 125, 817-825 (1998).	<input type="checkbox"/>
27	FRANK et al., "Identification of copper/zinc superoxide dismutase as a novel nitric oxide-regulated gene in rat glomerular mesangial cells and kidneys of endotoxemic rats", in: FASEB J. Vol. 13, 869-882 (1999).	<input type="checkbox"/>
28	SEEMA et al., "Serum TNF-Alpha and Free Radical Scavengers in Neonatal Septicemia", in: Indian J. Pediatr. 1999; 66: 511-516.	<input type="checkbox"/>
29	DUBEY et al., "Free Oxygen radicals in acute renal failure", in: Indian Pediatrics 2000; 37: 153-158.	<input type="checkbox"/>
30	KHARB et al., "Role of Oxygen Free Radicals in Shock", JAPI 2000; Vol. 48(10): 956-957.	<input type="checkbox"/>
31	FRANK et al., "Identification of copper/zinc dismutase as a nitric oxide-regulated gene in human (HaCaT) keratinocytes: Implications for keratinocyte proliferation", in Biochem. J. (2000) 346, 719-728.	<input type="checkbox"/>
32	BATRA et al., "Alterations in antioxidant status during neonatal sepsis", in: Ann.Trop.Paediatrics (2000) 20, 27-33.	<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10597619
Filing Date	2006-08-01
First Named Inventor	BERGMANN et al.
Art Unit	
Examiner Name	
Attorney Docket Number	2582.013

33	BELA et al., "Oxidative stress status: possible guideline for clinical management of critically ill patients", in: Panminerva Med 2001; 43(1): 27-31.	<input type="checkbox"/>
34	YASUDA et al., "Prognostic significance of serum superoxide dismutase activity in patients with gastric cancer", in: Gastric Cancer 2002; 5(3): 148-53.	<input type="checkbox"/>
35	TAYSI et al., "Lipid peroxidation, some extracellular antioxidants, and antioxidant enzymes in serum of patients with rheumatoid arthritis", in: Rheumatol Int 2002; 21(5): 200-204.	<input type="checkbox"/>
36	MARIKOVSKY et al., "Cu/Zn Superoxide Dismutase Plays Important Role in Immune Response", J. Immunol., 2003, 170: 2993-3001.	<input type="checkbox"/>
37	LAWLER et al., "Specificity of antioxidant enzyme inhibition in skeletal muscle to reactive nitrogen species donors", in: Biochem Biophys Res Commun. 294(2002) 1093-1100.	<input type="checkbox"/>
38	MONDOLA et al., "The Cu,Zn superoxide dismutase in neuroblastoma SK-N-BE cells is exported by a microvesicles dependent pathway", in: Mol. Brain Res. 110(2003) 45-51.	<input type="checkbox"/>
39	International Search Report for corresponding European Patent Application PCT/EP2005/001037.	<input type="checkbox"/>
40		<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

**EXAMINER SIGNATURE**

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> See Kind Codes of USPTO Patent Documents at [www.USPTO.GOV](http://www.USPTO.GOV) or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10597619
Filing Date	2006-08-01
First Named Inventor	BERGMANN et al.
Art Unit	
Examiner Name	
Attorney Docket Number	2582.013

**CERTIFICATION STATEMENT**

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

**OR**

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to  any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

- See attached certification statement.  
 Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.  
 None

**SIGNATURE**

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Kathy Smith Dias/	Date (YYYY-MM-DD)	2007-09-11
Name/Print	Kathy Smith Dias	Registration Number	41707

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

## Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.